Steminent Biotherapeutics (7729) Stock Overview
Operates as a biopharmaceutical company in Taiwan and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
7729 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Steminent Biotherapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$77.70 |
| 52 Week High | NT$95.60 |
| 52 Week Low | NT$27.05 |
| Beta | 0.15 |
| 1 Month Change | 3.74% |
| 3 Month Change | 3.60% |
| 1 Year Change | 174.07% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 93.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7729 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | -1.6% | 18.4% | 11.7% |
| 1Y | 174.1% | 75.1% | 83.1% |
Return vs Industry: 7729 exceeded the TW Biotechs industry which returned 75.1% over the past year.
Return vs Market: 7729 exceeded the TW Market which returned 83.1% over the past year.
Price Volatility
| 7729 volatility | |
|---|---|
| 7729 Average Weekly Movement | 6.9% |
| Biotechs Industry Average Movement | 6.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in TW Market | 12.2% |
| 10% least volatile stocks in TW Market | 2.7% |
Stable Share Price: 7729 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 7729's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Ling-Mei Wang | steminent.com |
Steminent Biotherapeutics Inc. operates as a biopharmaceutical company in Taiwan and the United States. It provides Stemchymal, a cell therapy product for the treatment of neurodegenerative diseases, including spinocerebellar ataxia and huntington’s disease; tissue regeneration, such as osteoarthritis; and acute syndromes consisting acute respiratory distress syndrome, liver failure, and ischemic stoke. The company was founded in 2009 and is based in Taipei, Taiwan.
Steminent Biotherapeutics Inc. Fundamentals Summary
| 7729 fundamental statistics | |
|---|---|
| Market cap | NT$5.18b |
| Earnings (TTM) | -NT$174.04m |
| Revenue (TTM) | n/a |
Is 7729 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7729 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$785.00k |
| Gross Profit | -NT$785.00k |
| Other Expenses | NT$173.25m |
| Earnings | -NT$174.04m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 3.6% |
How did 7729 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 16:48 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Steminent Biotherapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.